Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholestech seeks test reclassification under CLIA

This article was originally published in Clinica

Executive Summary

Now that the US CDC has resumed reviewing requests for waiver of specific CLIA requirements for laboratory testing devices, Cholestech has filed a petition seeking reclassification of its LDX System. The CDC lifted the moratorium on classifying testing devices as waived tests in December. Cholestech believes its total cholesterol, HDL cholesterol, triglycerides and glucose tests meet criteria to reclassify them from moderately complex to waived under CLIA '88.

Topics

UsernamePublicRestriction

Register

MT090476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel